The 10 most recent market catalysts affecting $NVAX, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 2, 2026
Corporate Catalyst
Bullish
Impact 65
Novavax Stock Rises Despite No Confirmed News Behind the Matrix-M Rumor
Novavax (NVAX) stock is experiencing a rise, primarily attributed to an unconfirmed rumor circulating among retail traders regarding its Matrix-M adjuvant. The rumor suggests a fav…
Sep 1, 2026
Corporate Catalyst
Bullish
Impact 75
Novavax shares are trading higher. Strength may be due to an increase in investor attention related to an unconfirmed rumor suggesting that Matrix-M has a favorable safety profile with mostly mild-to-moderate, self-limiting side effects.
This headline indicates a significant positive catalyst for Novavax, driven by an unconfirmed rumor about its Matrix-M adjuvant's safety profile. If true, a favorable safety profil…
Sep 1, 2026
Corporate Catalyst
Bullish
Impact 75
Watching Novavax; Shares Trading Higher In The Session, Traders Circulate Unconfirmed Rumor Suggesting Clinical Data Show That Matrix-M Has A Favorable Safety Profile With Mostly Mild-To-Moderate, Self-Limiting Side Effects
The unconfirmed rumor regarding Novavax's Matrix-M adjuvant having a favorable safety profile is a significant corporate catalyst. Positive clinical data, especially concerning saf…
Aug 31, 2026
Corporate Catalyst
Bullish
Impact 85
Novavax Stock Climbs Monday: What's Going On?
Novavax received regulatory approvals from the U.S. FDA, EU, and Japan for its updated COVID-19 vaccine, Nuvaxovid, ahead of the 2026-2027 autumn vaccination campaign. This validat…
Aug 28, 2026
Corporate Catalyst
Bullish
Impact 65
Novavax's Partners Receive Approvals For Nuvaxovid Formulation To Target SARS-CoV-2 XFG Variant
Novavax's partners have successfully obtained approvals for the Nuvaxovid formulation targeting the SARS-CoV-2 XFG variant for the 2026-2027 vaccination season in major markets inc…
Aug 25, 2026
Corporate Catalyst
Bullish
Impact 75
Novavax Stock Rallies Tuesday: What's Happening?
Novavax (NVAX) is experiencing a significant rally driven by a confluence of factors. Firstly, broader positive sentiment in the vaccine and mRNA sector, sparked by Moderna and Mer…
Aug 19, 2026
Corporate Catalyst
Bullish
Impact 65
Novavax Stock Moves Higher Wednesday: What's Driving the Action?
Novavax's stock is rising not due to its own direct news, but as a beneficiary of a significant clinical breakthrough by Merck and Moderna in the oncology space. Their successful P…
Aug 6, 2026
Corporate Catalyst
Bullish
Impact 75
Novavax Raises FY2026 Sales Guidance from $230.000M-$270.000M to $235.000M-$275.000M vs $389.234M Est
Novavax has updated its financial outlook for FY2026, increasing its sales guidance from $230M-$270M to $235M-$275M. While an upward revision typically signals positive momentum, t…
Aug 6, 2026
Corporate Catalyst
Bullish
Impact 75
Novavax Q2 EPS $(0.32) Beats $(0.37) Estimate, Sales $56.698M Beat $52.513M Estimate
This headline represents a positive corporate catalyst for Novavax. Beating both EPS and sales estimates suggests that the company is performing better than analysts anticipated, w…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.